SSY Group (02005.HK): All 16 Specifications of 13 Pharmaceutical Varieties Proposed to Be Selected in the 12th National Centralized Drug Procurement

NewTimeSpace News: SSY Group (02005.HK) released a voluntary announcement on 3 August 2026. In the recent bidding of China’s 12th National Centralized Drug Procurement, all 16 specifications of 13 varieties submitted by the Group are proposed to be selected, namely: Blonanserin Tablets (4mg), Betahistine Mesilate Tablets (6mg), Vitamin B6 Injection (1ml:0.1g), Acipimox Capsules (0.25g), Doxazosin Mesilate Sustained-release Tablets (4mg), Bisoprolol Amlodipine Tablets, Perindopril Amlodipine Tablets (III), Nicardipine Hydrochloride Injection (10ml:10mg) and Nicardipine Hydrochloride Sodium Chloride Injection, Bumetanide Injection (2ml:1mg and 1ml:0.5mg), Pentoxifylline Sustained-release Tablets (0.4g), Deferasirox Dispersible Tablets (125mg), Compound Potassium Hydrogen Phosphate Injection (5ml and 2ml), Calcium Chloride Injection (10ml:1g).

The Group stated that it actively complies with the policy direction of centralized drug procurement, strives to raise the market share of its products, leverages the advantages of integrated raw material and preparation production as well as large-scale manufacturing to effectively control production costs. The Group will continuously supply high-quality products and consolidate its market competitiveness.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.